“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome

We recently found that trastuzumab benefit may be lower in a small subset of early breast cancer (BC) patients (pts) with tumors expressing high levels of both hormonal receptors (HRs), i.e. triple positive (TP). To better investigate the role of HRs in HER2 positive BC, we retrospectively identifie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Vici, Patrizia, Pizzuti, Laura, Sperduti, Isabella, Frassoldati, Antonio, Natoli, Clara, Gamucci, Teresa, Tomao, Silverio, Michelotti, Andrea, Moscetti, Luca, Gori, Stefania, Baldini, Editta, Giotta, Francesco, Cassano, Alessandra, Santini, Daniele, Giannarelli, Diana, Di Lauro, Luigi, Corsi, Domenico Cristiano, Marchetti, Paolo, Sini, Valentina, Sergi, Domenico, Barba, Maddalena, Maugeri-Saccà, Marcello, Russillo, Michelangelo, Mentuccia, Lucia, D'Onofrio, Loretta, Iezzi, Laura, Scinto, Angelo Fedele, Da Ros, Lucia, Bertolini, Ilaria, Basile, Maria Luisa, Rossi, Valentina, De Maria, Ruggero, Montemurro, Filippo
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4951261/
https://ncbi.nlm.nih.gov/pubmed/26910921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7480
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados